{
"desc": [
{"id": "1", "text": "Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation."}
],
"crit": [
{"id": "1", "type": "inc", "text": "Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue."},
{"id": "2", "type": "inc", "text": "Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment."},
{"id": "3", "type": "exc", "text": "Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510)."},
{"id": "4", "type": "exc", "text": "Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab)."},
{"id": "5", "type": "exc", "text": "Active brain metastasis"}
]
}

{
  "extractedEligibilityCriteria": {
    "inclusionCriteria": [
      {
        "number": 1,
        "criterion": "Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue."
      },
      {
        "number": 2,
        "criterion": "Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment."
      }
    ],
    "exclusionCriteria": [
      {
        "number": 1,
        "criterion": "Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510)."
      },
      {
        "number": 2,
        "criterion": "Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab)."
      },
      {
        "number": 3,
        "criterion": "Active brain metastasis."
      }
    ]
  },
  "fhirQueryPredicates": {
    "inclusionCriteriaPredicates": [
      {
        "criterionNumber": 1,
        "order": 1,
        "fhirPredicate": "_has:Condition:patient:code=http%3A%2F%2Fsnomed.info%2Fsct%7C363406005&_has:Observation:patient:code=http%3A%2F%2Floinc.org%7C81247-9",
        "explanation": "Diagnosis of colorectal carcinoma (SNOMED CT: 363406005) with KRAS G12C mutation (LOINC: 81247-9)."
      },
      {
        "criterionNumber": 2,
        "order": 2,
        "fhirPredicate": "_has:MedicationStatement:patient:medication.code=http%3A%2F%2Frxnorm.info%2F%7C308056&_has:MedicationStatement:patient:medication.code=http%3A%2F%2Frxnorm.info%2F%7C308057",
        "explanation": "Prior treatment with oxaliplatin (RxNorm: 308056) or irinotecan (RxNorm: 308057) in a fluoropyrimidine-based regimen."
      }
    ],
    "exclusionCriteriaPredicates": [
      {
        "criterionNumber": 1,
        "order": 1,
        "fhirPredicate": "_has:MedicationStatement:patient:medication.code:not=http%3A%2F%2Frxnorm.info%2F%7C2265747",
        "explanation": "No prior treatment with AMG 510 (RxNorm: 2265747)."
      },
      {
        "criterionNumber": 2,
        "order": 2,
        "fhirPredicate": "_has:MedicationStatement:patient:medication.code:not=http%3A%2F%2Frxnorm.info%2F%7C1802&_has:MedicationStatement:patient:medication.code:not=http%3A%2F%2Frxnorm.info%2F%7C1803",
        "explanation": "No prior treatment with cetuximab (RxNorm: 1802) or panitumumab (RxNorm: 1803)."
      },
      {
        "criterionNumber": 3,
        "order": 3,
        "fhirPredicate": "_has:Condition:patient:code:not=http%3A%2F%2Fsnomed.info%2Fsct%7C443527001",
        "explanation": "No active brain metastasis (SNOMED CT: 443527001)."
      }
    ]
  },
  "rationale": {
    "assumptions": [
      "KRAS G12C mutation is recorded as a genetic observation.",
      "Fluoropyrimidine-based chemotherapy regimens are inferred from the presence of oxaliplatin or irinotecan."
    ],
    "notes": [
      "Reverse chaining is used to connect Patient resources with related Condition, Observation, and MedicationStatement resources.",
      "URL encoding is applied to special characters in FHIR predicates to ensure proper query execution."
    ]
  }
}